BR9910590A - Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada - Google Patents
Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediadaInfo
- Publication number
- BR9910590A BR9910590A BR9910590-0A BR9910590A BR9910590A BR 9910590 A BR9910590 A BR 9910590A BR 9910590 A BR9910590 A BR 9910590A BR 9910590 A BR9910590 A BR 9910590A
- Authority
- BR
- Brazil
- Prior art keywords
- retina
- optic nerve
- blood flow
- retinal diseases
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
"COMPOSTO, PROCESSOS PARA DIMINUIR IOP, PARA MELHORAR O FLUXO SANGuìNEO PARA A EXTREMIDADE DO NERVO óPTICO E A RETINA, E PARA TRATAR DOENçAS RETINAIS, COMPOSIçõES PARA DIMINUIR IOP, PARA MELHORAR O FLUXO SANGuìNEO PARA A EXTREMIDADE DO NERVO óPTICO E A RETINA, E PARA TRATAR DOENçAS RETINAIS, PROCESSO E COMPOSIçãO PARA PROVER NEUROPROTEçãO PARA A EXTREMIDADE DO NERVO óPTICO OU A RETINA, E, PROCESSO PARA TRATAR PESSOAS SOFRENDO DE DISTúRBIOS DO SONO, DEPRESSãO, ESQUIZOFRENIA, ANSIEDADE, DISTúRBIOS RìTMICOS CIRCADIANOS E HIPERTENSãO CENTRALMENTE E PERIFERICAMENTE MEDIADA" Compostos com afinidade para receptor 5HT~ 7~ (alguns dos quais são novos) utilizáveis para diminuir IOP, melhorar o fluxo sang³íneo para a extremidade de nervo óptico e a retina, prover neuroproteção e tratar doenças retinais são descritos. Os compostos são também utilizáveis para o tratamento de distúrbios do sono, depressão, e outros distúrbios psiquiátricos, como esquizofrenia, ansiedade, distúrbio compulsivo obsessivo, distúrbios do ritmo circadiano, e hipertensão centralmente e perifericamente mediada. As composições e processos para seu uso também são descritos.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8600598P | 1998-05-19 | 1998-05-19 | |
US8600698P | 1998-05-19 | 1998-05-19 | |
US8598998P | 1998-05-19 | 1998-05-19 | |
US8600298P | 1998-05-19 | 1998-05-19 | |
PCT/US1999/010179 WO1999059499A2 (en) | 1998-05-19 | 1999-05-10 | Serotonergic 5ht7 receptor compounds for treating ocular and cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9910590A true BR9910590A (pt) | 2001-01-23 |
Family
ID=27491993
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9910590-0A BR9910590A (pt) | 1998-05-19 | 1999-05-10 | Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1079763A2 (pt) |
JP (1) | JP2002515408A (pt) |
CN (1) | CN1301161A (pt) |
AU (1) | AU3978899A (pt) |
BR (1) | BR9910590A (pt) |
CA (1) | CA2332505A1 (pt) |
WO (1) | WO1999059499A2 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6960579B1 (en) | 1998-05-19 | 2005-11-01 | Alcon Manufacturing, Ltd. | Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders |
GB9828004D0 (en) * | 1998-12-18 | 1999-02-10 | Smithkline Beecham Plc | Use |
WO2000069437A1 (en) | 1999-05-18 | 2000-11-23 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
KR20030065304A (ko) * | 2000-03-17 | 2003-08-06 | 알콘, 인코퍼레이티드 | 녹내장 치료용 6-하이드록시-인다졸 유도체 |
US6956036B1 (en) | 2000-03-17 | 2005-10-18 | Alcon, Inc. | 6-hydroxy-indazole derivatives for treating glaucoma |
BR0017163A (pt) * | 2000-03-17 | 2003-01-14 | Alcon Inc | Derivados 5-hidróxi-indazol para tratamento do glaucoma |
US7005443B1 (en) | 2000-03-17 | 2006-02-28 | Alcon, Inc. | 5-Hydroxy indazole derivatives for treating glaucoma |
US6630469B2 (en) | 2000-05-09 | 2003-10-07 | Bristol-Myers Squibb Company | 5-HT7 receptor antagonists |
TW593302B (en) | 2001-12-20 | 2004-06-21 | Alcon Inc | Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma |
WO2004054572A2 (en) | 2002-12-13 | 2004-07-01 | Alcon, Inc. | Novel benzopyran analogs and their use for the treatment of glaucoma |
AR046890A1 (es) | 2003-12-15 | 2005-12-28 | Alcon Inc | [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma. |
US7129257B1 (en) | 2003-12-15 | 2006-10-31 | Alcon, Inc. | Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma |
US7338972B1 (en) | 2003-12-15 | 2008-03-04 | Alcon, Inc. | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma |
WO2006062839A1 (en) | 2004-12-08 | 2006-06-15 | Alcon, Inc. | Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5880134A (en) * | 1996-03-20 | 1999-03-09 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor |
-
1999
- 1999-05-10 BR BR9910590-0A patent/BR9910590A/pt not_active Application Discontinuation
- 1999-05-10 JP JP2000549166A patent/JP2002515408A/ja active Pending
- 1999-05-10 CA CA002332505A patent/CA2332505A1/en not_active Abandoned
- 1999-05-10 CN CN99806330A patent/CN1301161A/zh active Pending
- 1999-05-10 WO PCT/US1999/010179 patent/WO1999059499A2/en not_active Application Discontinuation
- 1999-05-10 AU AU39788/99A patent/AU3978899A/en not_active Abandoned
- 1999-05-10 EP EP99922894A patent/EP1079763A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN1301161A (zh) | 2001-06-27 |
WO1999059499A3 (en) | 2000-03-16 |
JP2002515408A (ja) | 2002-05-28 |
WO1999059499A2 (en) | 1999-11-25 |
AU3978899A (en) | 1999-12-06 |
EP1079763A2 (en) | 2001-03-07 |
CA2332505A1 (en) | 1999-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9910590A (pt) | Composto, processo para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, composições para diminuir iop, para melhorar o fluxo sanguìneo para a extremidade do nervo óptico e a retina, e para tratar doenças retinais, processo e composição para prover neuroproteção para a extremidade do nervo óptico ou a retina, e, processo para tratar pessoas sofrendo de distúrbios do sono, depressão, esquizofrenia, ansiedade, distúrbios rìtmicos circadianos e hipertensão centralmente e perifericamente mediada | |
BR9712824A (pt) | Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico | |
ES2253526T3 (es) | Derivados de carbonilo sustituidos heterociclicos y su uso como ligandos de receptores d3 de dopamina. | |
WO2005063297A3 (en) | Melatonin combination therapy for improving sleep quality | |
TW200607509A (en) | Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome | |
DE60222698D1 (de) | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 | |
WO2002066469A3 (en) | Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands | |
DK1049699T3 (da) | Pyrazolotriaziner som CRF-antagonister | |
DE69923998D1 (de) | Verwendung eines neurologischen wirkstoffes zur herstellung eines medikamentes zur behandlung von erkrankungen des zentralen nervensystems | |
WO2001093849A3 (en) | Treatment of gastroesophageal reflux disease using piperidine derivatives | |
BR9914128A (pt) | Composições antibióticas para tratamento do olho, ouvido e nariz | |
DE69618047D1 (de) | Verwendung von Serotonin- und Dopaminrezeptorblockern zur Behandlung von mentalen Erkrankungen verursacht durch zerebrovaskuläre Erkrankungen | |
BR9914848A (pt) | Composição e processo para o tratamento de distúrbios da retina externa | |
ATE310517T1 (de) | Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit | |
WO2002066468A3 (en) | Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands | |
BR0012408A (pt) | Métodos para induzir ou aumentar a migração celular, para reduzir ou inibir a migração celular, para induzir ou aumentar a cura de ferimento em um paciente, e para regular a expressão de pelo menos um gene de uma célula, e, uso de um agonista de fator de tecido | |
BR0314459A (pt) | Método para baixar e controlar a pressão intra-ocular e/ou para o tratamento de mamìferos sofrendo a partir de glaucoma e composto | |
ATE210980T1 (de) | Verwendung von indolderivaten zur behandlung von dermatologischen krankheiten, peridhren neuropathien, arthritis, allergischen oder chronisch-obstruktiven atemwegserkrankungen, glaukom und augenentzündungen | |
DE69028877D1 (de) | Verwendung von Phenylethanolaminen zur Herstellung von Medikamenten gegen Augenleiden | |
BR9915803A (pt) | Composição para o tratamento de neuropatia da retina ou cabeça de nervo ótico, e, processo para tratamento de neuropatia da retina ou cabeça de nervo ótico | |
ATE253905T1 (de) | Verwendung von beta-rezeptorenblocker zur herstellung eines medikaments zur behandlung von krankheiten der äusseren retina | |
DK1756066T3 (da) | Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet | |
DE69906728D1 (de) | Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen | |
ATE539763T1 (de) | Verwendung des nervenwachstumfaktors in augentropfen zur behandlung von erkrankungen des zentralen nervensystems, wie z.b. alzheimer- krankheit und parkinson-krankheit | |
EP1632235A3 (en) | Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |